Filter Results
Clinical Studies
Results filtered:Study status:
Open
Closed for Enrollment
Closed for Enrollment
-
A Comparative Effectiveness Study In Heart Transplant Patients Of Rejection Surveillance With Cell-free DNA Versus Endomyocardial Biopsy (ACES-EMB)
Jacksonville, FL
The purpose of this study is to compare the effectiveness of rejection surveillance of heart transplant recipients with Prospera dd-cfDNA to rejection surveillance with endomyocardial biopsy (EMB) in the first post-transplant year.
-
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study To Evaluate The Efficacy And Safety Of Amyloid Depleter ALXN2220 In Adult Participants With Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Jacksonville, FL
The purpose of this study is to assess the effectiveness of ALXN2220 in the treatment of adult participants with ATTR-CM by evaluating the difference between the ALXN2220 and placebo groups as assessed by the composite endpoint of all-cause mortality (ACM) and total cardiovascular (CV) clinical events.
-
Development Of Non-invasive Cell-free DNA To Supplant Invasive Biopsy In Heart Transplant
Jacksonville, FL
The purpose of this study is to describe the association between Prospera dd-cfDNA measures and other diagnostic tests used to detect heart allograft rejection and/or njury, including histology, echocardiography and DSA, in the first post-transplant year. Additionally, to inform rates of clinical outcomes in a contemporary cohort of adult heart transplant recipients to determine power for a future randomized, controlled clinical trial.
-
Expanded Access Protocol Of Patisiran For Patients With Hereditary Transthyretin-Mediated Amyloidosis (HATTR Amyloidosis) With Polyneuropathy
Scottsdale/Phoenix, AZ
Jacksonville, FL
Rochester, MN
The purpose of this study is to provide expanded access of patisiran to patients with transthyretin-mediated amyloidosis (ATTR amyloidosis) with cardiomyopathy.
.